XPyto Executes Covid-ID Lab Sales Contracts with Testing Clinics and Pharmacies in Germany as Part of a Multi-Product Deployment Strategy
VANCOUVER, BC and UTTENWEILER, GERMANY/ACCESSWIRE/February 1, 2022/XPyto Therapeutics Corp. (CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT) (“XPyto” or the “Company”) is pleased to announce the execution of Covid-ID Lab’s sales contracts with both digital lives are Corona Testzentren (“digitallife”), powered by digitallifecare GmbH, Germany and a group of pharmacies in Bamberg, Germany.
Digitallife operates five coronavirus testing centers south of Stuttgart, Germany, serving a local community of approximately 75,000 people. Staff training and equipment installation were completed last week and the first order of test kits was delivered. In addition to tests for the general public, digitallife will also offer corporate clients in the region COVID-ID Lab PCR tests.
The company also began selling to pharmacies in Bamberg, Germany, serving a local community of approximately 78,000 people.
The Company expects to advance and execute additional sales contracts and will release details as they become available.
“Having recently joined the company to lead global marketing and sales initiatives, I am extremely pleased to announce today’s contracts,” said Roland Spleiss, Director of Business Development. “This is just one of many direct selling commitments we are currently pursuing in Germany, in addition to a number of European and global distribution deals that are under review. joint efforts of 3a and Vektor personnel, provide high-level training capabilities.
Covid-ID Lab is a rapid RT-PCR test for the qualitative detection of SARS-CoV-2 based on the reverse transcriptase polymerase chain reaction (RT-PCR) method. To perform the test, Covid-ID Lab only requires a PCR run time of 20 minutes with no prior RNA extraction as part of the sample preparation. The RT-PCR sampling process detects the SARS-CoV-2 virus on a test chip within 5 minutes, when SARS-CoV-2 is present, the result can be read visually immediately. Target customers are airports, cruise lines, pharmacies, medical clinics and any industrial or educational site requiring quick and definitive results.
The Company is pleased to have recently embarked on a rapid management change process focused on product marketing and sales. The company has a development pipeline for additional medical and oral health products that will be rolled out continuously with the commercialization team rapidly gaining traction and momentum. Information on product deployment strategies will be released in due course.
The Company makes no express or implied representation that its product has the ability to eliminate, cure, or contain the COVID-19 pandemic.
About XPyto Therapeutics Corp.
XPyto Therapeutics Corp. is a bioscience accelerator focused on next-generation drug delivery, diagnostics and new investment opportunities in active pharmaceutical ingredients, including: transdermal and oral precision soluble drug formulations; rapid and inexpensive diagnostic tests for infectious diseases and oral health; and the standardization of emerging active pharmaceutical ingredients for neurological applications, including psychedelic compounds and cannabinoids. The Company has research and development activities in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets.
XPyto Therapeutics Corp.
Hugh Rogers, CEO and Director
Mr. Knox Henderson
Phone. : 604-551-2360
This press release contains statements that contain forward-looking information within the meaning of applicable Canadian securities laws (“forward-looking statements”). Forward-looking statements are frequently characterized by words such as “develop”, “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “potential”, “propose” and other similar words or statements that certain events or conditions “may” or “will” occur, and in this release include the statement regarding the company’s purpose to build a successful diagnostics, drug distribution and medical cannabis company. Forward-looking statements are only predictions based on the opinions and estimates of management as of the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results differ materially from those projected in the forward-looking statements, including: that the Company may not be successful in developing a commercial product; that selling products may not be a viable business; that the Company may not be able to expand its business; product liability risks; product regulatory risk; general economic conditions; adverse industry events; future legislative and regulatory developments; inability to access sufficient capital from internal and external sources and/or inability to access sufficient capital on favorable terms; currency risks; competetion; international risks; and other risks beyond the Company’s control. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by applicable law. expressly requires. Neither the CSE nor its Market Regulator (as that term is defined in the CSE policies) accepts responsibility for the adequacy or accuracy of this press release.
THE SOURCE: XPyto Therapeutics Corp
See the source version on accesswire.com:
https://www.accesswire.com/686537/XPhyto-Executes-Covid-ID-Lab-Sales-Contracts-with-Test-Clinics-and-Pharmacies-in-Germany-as-Part-of-Multi-Product- Deployment Strategy